GlobeNewswire

NEP Showcases Innovative Solutions Supporting Discovery's Inaugural Olympics Coverage at NAB 2018

Dela

Pittsburgh, Pa. (USA), March 27, 2018 (GLOBE NEWSWIRE) -- NEP Group, the leading worldwide outsourced technical production partner of premier content producers of live sports and entertainment, is exhibiting at this year's NAB Show, weeks after successfully supporting multiple clients, including Discovery and its leading sports brand Eurosport, at the Olympic Winter Games PyeongChang 2018. Starting April 9, NEP staff will be on hand in NAB Booth 3714 in the South Upper Hall at the Las Vegas Convention Center to answer questions about its comprehensive set of broadcast, live event and media solutions used to cover over 100 medal events and 18 days of Olympic competition. Demonstrations of its media asset management tool, Mediabank, and NEP's augmented reality (AR) capabilities will be available at the show.

During the Games, 14 NEP Divisions provided its glass-to-glass solutions to enable Discovery to deliver its first-ever coverage of the Games across 48 countries in Europe on free-to-air, pay-tv and every minute online across the continent for the very first time. More than 20 venues were supported by 300 NEP technical experts on the ground in South Korea and 100 in NEP Europe locations, including 17 studios. The successful implementation of these solutions for Discovery was made possible through NEP's unique infrastructure, including several hubs and facilities across Europe.

"Discovery set the ambitious goal of reaching more people on more screens for the Olympic Winter Games than ever before, redefining the viewing experience for viewers and fans across Europe. It was a massive team effort to broadcast 4000 hours of coverage, in 48 markets, more than 20 languages and from multiple locations to millions of viewers across the continent," said Simon Farnsworth, Discovery Executive Vice President, European and Sports Technology. "We are pleased to have honoured this commitment at the Games. Critical to our success was enhancing our in-house capabilities with technical expertise proven at the biggest sporting events in the world.  NEP integrated seamlessly into our global operation and provided additional technical experts, innovative solutions and a true spirit of collaboration and partnership, on-site in South Korea and throughout Europe, which played a significant role in our delivery of the Games across Europe."

NEP's support of Discovery included:

  • Custom buildout of the International Broadcast Centre, which fully integrated more than 85 racks of equipment that underpinned its operations hub, production control rooms, audio suites and edit facilities supplied by NEP, supporting directors, producers, journalists and production engineers during the Games.
  • A virtual studio based in Hilversum, The Netherlands, for the fast-paced "Winter Games Today" live daily show on Eurosport 1 (Eurosport Benelux) and available for download through the Eurosport Player. Eurosport Benelux used the Hilversum virtual studio and NEP's AR capabilities as a replacement for a real studio. Only occupying a physical footprint of 5x5 meters, NEP's graphics teams transformed Eurosport's coffee corner into an entire virtual set (the "green box"), including a virtual LED wall and a number of AR layered elements.
  • An Oslo-based broadcast center built for Discovery Communications. As part, NEP supplied studios and facilities with AR graphics to support the daily production of multiple shows: OL Direkte: Studio ("Olympics Live: Studio"), OL i dag ("Olympics Today"), and OL-Kveld ("Late Night Olympics").
  • Mediabank, NEP's cloud-based toolbox of workflow solutions, to easily ingest, tag, review, edit and distribute Discovery's content across a dozen European viewing markets.

NEP's broadcast services, including seven outside broadcast/mobile units, snowmobile coverage, flypacks and more, rounded out these solutions for clients.

"It has been a tremendous opportunity and privilege to support Discovery on their inaugural Olympic Games," said Keith Lane, Vice President of Client Services for Discovery / Eurosport, NEP UK. "NEP is unique in the industry in that we have the depth of technical talent and diversity of service offerings to be able to deliver this kind of large-scale support. This event was special in comparison to anything we've done before - the number of countries, regions, cultures and languages involved, plus the complexity of our solutions, was staggering. We have some of the best people in the business, and I'm proud of what they did and how much they accomplished for our clients. We are very much looking forward to working with Discovery's team again."

To learn more about NEP's solutions and to see demonstrations of NEP's Mediabank and AR solutions, visit NEP at Booth 3714, South Hall (Upper Level), at NAB 2018. Or, contact us at nepgroup.com.

###

About NEP

For over 30 years, NEP has been a worldwide outsourced technical production partner supporting premier content producers of live sports, entertainment, music and corporate events. Our services include remote production, studio production, audio visual solutions, host broadcast support, premium playout, post production and innovative software-based media management solutions. NEP's 3,000+ employees are driven by a passion for superior service and a focus on technical innovation. Together, we have supported productions in over 85 countries on all seven continents.

NEP is headquartered in the United States and has offices in 22 countries.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/fb3ca366-951f-4e9e-879d-27068f9680c4

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1717cc0e-cb44-4d61-b4c3-009593097534

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4457f739-7076-43f6-925e-d2f2e7a0d9b4

Susan Matis
NEP Group, Inc.
412-423-1339
press@nepgroup.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NEP via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum